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INTRODUCTION
Takayasu arteritis (TAK) is a large-vessel vasculitis character-
ized by inflammation of the aorta and its major branches.1 For 
its treatment, it is important to detect active inflammation early 
in the disease and treat it accordingly before the occurrence of 
irreversible structural vessel damage, such as stenosis or aneu-
rysmal change.2 However, assessing the disease activity of TAK 
is challenging as clinical symptoms and laboratory data do not 
precisely reflect the actual inflammation of the arterial wall, which 
makes it difficult to effectively monitor and treat the disease.2-4
18F-fluorodeoxyglucose positron emission tomography/com-
puted tomography (18F-FDG PET/CT) has been suggested as a 
useful diagnostic tool for large vessel vasculitis.5,6 Moreover, sev-
eral studies have demonstrated the value of 18F-FDG PET/CT in 
assessing the disease activity of TAK.7-12 The sensitivity and spec-
ificity of 18F-FDG PET/CT in detecting the clinically active state 
of the disease have been reported to be 75%–100% and 64.3%–
88.9%, respectively.7-9,11 Notably, the specificity was relatively 
low, implicating that a substantial proportion of patients with 
a clinically inactive state of the disease may have vascular up-
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take on 18F-FDG PET/CT. Although previous studies have re-
ported that clinically inactive patients with vascular uptake on 
18F-FDG PET/CT exist,7-10 the clinical significance of vascular 
uptake on 18F-FDG PET/CT in patients with clinically inactive 
TAK remains unclear. Given that TAK is an inflammatory dis-
ease that primarily affects vessels (large vessels in particular),1 
vascular uptake on 18F-FDG PET/CT during the clinically in-
active state of the disease might be associated with future re-
lapse. In this study, we aimed to evaluate whether vascular 
uptake on 18F-FDG PET/CT during clinically inactive disease 
in patients with TAK are associated with disease relapse.
MATERIALS AND METHODS
Patients
Patients with TAK who underwent an 18F-FDG PET/CT between 
2006 and 2019 at two tertiary referral hospitals were retrospec-
tively screened for inclusion. All patients fulfilled the American 
College of Rheumatology 1990 criteria for the classification of 
TAK.13 Patients with clinically active disease at the time of 18F-
FDG PET/CT were excluded, and the remaining patients who 
had clinically inactive disease at the time of 18F-FDG PET/CT 
were included for the analysis. All of the included patients un-
derwent 18F-FDG PET/CT for further evaluation of disease ac-
tivity, despite the clinically inactive disease state. The timing of 
18F-FDG PET/CT was at the investigator’s discretion. None of 
the patients had experienced relapse prior to the date of 18F-
FDG PET/CT. The following data at the time of 18F-FDG PET/
CT were reviewed: age, sex, disease duration, presence of hy-
pertension, diabetes mellitus, and dyslipidemia, smoking status 
(current smoker or not), body mass index, erythrocyte sedimen-
tation rate (ESR), C-reactive protein (CRP), vascular involve-
ment pattern according to the Hata classification,14 and current 
use of glucocorticoids and immunosuppressants (methotrex-
ate or azathioprine).
This study was conducted in accordance with the Declara-
tion of Helsinki, and was approved by the Institutional Review 
Board of Gangnam Severance Hospital (approval no. 3-2019-
0423). The requirement for informed consent was waived ow-
ing to the retrospective nature of this study.
Definition of clinically inactive disease and relapse
Clinically inactive disease was defined as a status not meeting 
the National Institutes of Health (NIH) criteria for active disease 
in TAK.2 According to the NIH criteria, new onset or worsening 
of two or more of the following criteria indicates active disease: 
criterion 1, systemic features such as fever or arthralgia; criterion 
2, elevated ESR; criterion 3, features of vascular ischemia or in-
flammation; and criterion 4, typical angiographic features.2 The 
NIH criterion 4 was assessed based on CT or magnetic resonance 
angiography that was performed at the closest date (within 1 
month in all cases) to the date 18F-FDG PET/CT was performed. 
Due to the heterogeneity of angiographic modalities, worsen-
ing of angiographic features was confined to worsening of lu-
minal changes in the affected vessels. The fulfillment of each 
criterion at the time of 18F-FDG PET/CT was retrospectively re-
viewed. Relapse was defined as a recurrence of clinically active 
disease (based on the NIH criteria) after a period of clinically 
inactive disease, necessitating an increase in the prednisone 
dose of ≥10 mg/day from the basal dose and/or the addition of 
glucocorticoid-sparing therapy. The retrospective observation 
period was from the time of 18F-FDG PET/CT to the last follow-
up date or the occurrence of relapse, whichever came first.
18F-FDG PET/CT
18F-FDG PET/CT scans were obtained using a dedicated PET/
CT scanner [Discovery STE (GE Healthcare, Chicago, IL, USA) 
or Biograph 40 TruePoint (Siemens Medical Systems, Erlangen, 
Germany)], as previously described.15 The dose of 18F-FDG was 
5.5 MBq/kg. The images were interpreted by a nuclear physi-
cian who was blinded to the clinical data. As used in previous 
studies,16,17 the target/background ratio (TBR) was assessed as 
a parameter of vascular uptake. TBR was calculated as arterial 
maximum standardized uptake value (max SUV)/mean SUV 
in background reference tissue. The arterial max SUV was de-
fined as the highest value in a slice-by-slice analysis of the en-
tire aorta and its major branches. The mean SUV in background 
reference tissue was measured in venous blood pool.
Statistical analysis
The patient characteristics are summarized as median (inter-
quartile range) for continuous variables and as number (%) for 
categorical variables. For comparison between patients who 
did and did not experience relapse, the Mann-Whitney U-test 
was performed for continuous variables and Fisher’s exact test 
was used for categorical variables. Multivariable Cox propor-
tional hazard regression analysis with a stepwise backward elimi-
nation procedure was used to identify factors associated with 
relapse. The proportional hazard assumption was confirmed by 
examination of log [-log (survival)] curves and by testing Schoen-
feld partial residuals, which revealed no relevant violation. Fac-
tors with a p value of <0.05 in univariable analysis were includ-
ed in multivariable analysis. To assess the predictive accuracy 
and determine the cut-off value of TBR that best predicts relapse, 
we performed a receiver-operating characteristic (ROC) anal-
ysis. Relapse-free survival rates were analyzed using the Kaplan-
Meier survival analysis and were compared using the log-rank 
test. All analyses were performed using the SPSS software (ver-
sion 25.0; IBM Corp., Armonk, NY, USA).
RESULTS
Patient characteristics
A total of 33 patients with TAK who underwent 18F-FDG PET/
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CT during the clinically inactive state of the disease were iden-
tified. The characteristics of patients at the time of 18F-FDG PET/
CT are summarized in Table 1. The median patient age was 49.0 
(38.0–55.0) years, and majority of the patients were female (30 
of 33, 90.9%). The median disease duration of TAK at the time 
of 18F-FDG PET/CT was 4.0 (1.0–10.0) years. During a median 
observation period of 4.5 (0.9–8.1) years, relapse occurred in 9 
(27.3%) patients at a median of 1.3 (0.7–6.9) years. The median 
values of arterial max SUV, mean SUV in blood pool, and TBR 
were 2.3 (1.9–2.9) g/mL, 1.7 (1.5–2.3) g/mL, and 1.4 (1.2–1.6), 
respectively.
Comparison between patients who did and did not 
experience relapse
Patients who experienced relapse had longer disease duration 
[10.0 (3.5–16.5) years vs. 3.5 (0.8–5.8) years, p=0.029], higher ESR 
[26.0 (19.0–32.5) mm/h vs. 18.0 (10.8–20.0) mm/h, p=0.010] and 
CRP [3.2 (0.8–4.3) mg/L vs. 1.0 (0.6–1.3) mg/L, p=0.049), more 
commonly fulfilled NIH criterion 2 (77.8% vs. 16.7%, p=0.002), 
and less commonly fulfilled NIH criterion 4 (0.0% vs. 50.0%, 
p=0.012), compared to patients who did not experience re-
lapse. Notably, the TBR [1.5 (1.3–1.8) vs. 1.3 (1.1–1.4), p=0.044] 
was significantly higher in patients who experienced relapse 
than in those who did not (Fig. 1). On the other hand, there was 
no significant difference in age (p=0.766), sex distribution (p> 
0.999), BMI (p=0.453), type of vascular involvement (type I, p= 
0.394; type IIA, p=0.555; type IIB, p=0.651; type III, p=0.273; and 
type V, p=0.690), fulfillment of NIH criterion 1 (p=0.477) and 
NIH criterion 3 (p=0.477), arterial max SUV (p=0.486), mean 
SUV in IVC (p=0.166), use and dose of glucocorticoids (p>0.999 
and p=0.648, respectively), and use of methotrexate (p>0.999) 
and azathioprine (p=0.477) between the two groups (Table 2).
Among the total 33 patients with clinically inactive TAK, one 
patient with a TBR of 1.6 was newly administered prednisolone 
at a dose of 10 mg/day based on the 18F-FDG PET/CT result. No 
disease relapse was noted in this patient during the observation 
period.
Factors associated with relapse
On univariable analysis, ESR [unadjusted hazard ratio (HR): 
1.112, 95% confidence interval (CI): 1.035–1.195, p=0.004], CRP 
(unadjusted HR: 1.573, 95% CI: 1.005–2.460, p=0.047), presence 
of NIH criterion 2 (comparison with absence of NIH criterion 
2) (unadjusted HR: 8.210, 95% CI: 1.688–39.927, p=0.009), and 
TBR (unadjusted HR: 14.751, 95% CI: 1.484–146.663, p=0.022) 
had a p value of <0.05. Among these variables, ESR and CRP 
were not included in the multivariable analysis owing to mul-
ticollinearity with NIH criterion 2. On multivariable analysis, 
Table 1. Characteristics of the 33 Patients with Clinically Inactive TAK
Age at 18F-FDG PET/CT, yr 49.0 (38.0–55.0)
Female sex 30 (90.9)
Disease duration, yr 4.0 (1.0–10.0)
Hypertension 16 (48.5)
Diabetes mellitus 2 (6.1)
Dyslipidemia 14 (42.4)
Smoking 3 (9.1)
BMI, kg/m2 22.2 (21.6–24.8)
ESR, mm/h 19.0 (11.5–24.0)
CRP, mg/L 1.0 (0.6–2.8)







NIH criterion 1 2 (6.1)
NIH criterion 2 11 (33.3)
NIH criterion 3 2 (6.1)
NIH criterion 4 12 (36.4)
Fulfillment of no NIH criteria 6 (18.2)
Fulfillment of one NIH criterion 27 (81.8)
Arterial max SUV, g/mL 2.3 (1.9–2.9)
Mean SUV in blood pool, g/mL 1.7 (1.5–2.3)
TBR 1.4 (1.2–1.6)
Medications at 18F-FDG PET/CT
Glucocorticoid 13 (39.4)
Glucocorticoid dose*, mg/d 0.0 (0.0–5.0)
Methotrexate 7† (21.2)
Azathioprine 2‡ (6.1)
TAK, Takayasu arteritis; 18F-FDG PET/CT, 18F-fluorodeoxyglucose positron 
emission tomography/computed tomography; IQR, interquartile range; BMI, 
body mass index; ESR, erythrocyte sedimentation rate; CRP, C-reactive pro-
tein; NIH, National Institutes of Health; SUV, standardized uptake value; TBR, 
target/background ratio.
Data are presented as median (IQR) or n (%).
*Equivalent to prednisolone, †Median dose: 10.0 (IQR 7.5–15.0) mg/week, 
‡Both patients received 100 mg/d.
Fig. 1. Comparison of TBR in patients who did and did not relapse. The 
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the presence of NIH criterion 2 (comparison with absence of 
NIH criterion 2) (adjusted HR: 7.044, 95% CI: 1.424–34.855, p= 
0.017) and TBR (adjusted HR: 11.533, 95% CI: 1.053–126.282, 
p=0.045) were significantly associated with an increased risk of 
relapse (Table 3).
Predictive accuracy and cut-off value of TBR and 
relapse-free survival according to TBR
The ROC curve assessing the predictive accuracy of TBR for re-
lapse is shown in Fig. 2A. The area under the curve (AUC) of 
TBR was 0.731, and the cut-off value of TBR that best predict-
ed relapse was 1.46. When TBR was used in combination with 
NIH criterion 2 as a composite parameter, the AUC was higher 
(Fig. 2B, AUC=0.903). Using the TBR cut-off value of 1.46, we 
divided the patients into high TBR (n=13) and low TBR (n=20) 
groups. The high TBR group had a significantly lower relapse-
free survival compared to the low TBR group (p=0.019) (Fig. 3).
DISCUSSION
In this study, we demonstrated that the vascular uptake on 18F-
FDG PET/CT, as assessed by TBR, and the presence of NIH cri-
terion 2 during the clinically inactive state of the disease in TAK 
are associated with an increased risk of relapse. This finding has 
an important clinical implication, as it may aid in identifying pa-
tients with inactive disease who are at a higher risk of relapse.
Tezuka, et al.16 compared 18F-FDG uptake between patients 
with relapsed TAK (defined as active disease while receiving im-
munosuppressants) and patients with inactive TAK who were 
Table 2. Comparison of Patients according to the Occurrence of Relapse
Relapse occurred (n=9) Relapse did not occur (n=24) p value
Age at 18F-FDG PET/CT, yr 50.0 (26.5–57.0) 49.5 (45.0–55.0) 0.766
Female sex 8 (88.9) 22 (91.7) >0.999
Disease duration, yr 10.0 (3.5–16.5) 3.5 (0.8–5.8) 0.029
Hypertension 5 (55.6) 11 (45.8) 0.708
Diabetes mellitus 1 (11.1) 1 (4.2) 0.477
Dyslipidemia 3 (33.3) 11 (45.8) 0.698
Smoking 1 (11.1) 2 (8.3) >0.999
BMI, kg/m2 22.1 (21.7–24.1) 22.4 (21.3–25.1) 0.453
ESR, mm/h 26.0 (19.0–32.5) 18.0 (10.8–20.0) 0.010
CRP, mg/L 3.2 (0.8–4.3) 1.0 (0.6–1.3) 0.049
Type of vascular involvement
I 1 (11.1) 7 (29.2) 0.394
IIA 0 (0.0) 4 (16.7) 0.555
IIB 3 (33.3) 5 (20.8) 0.651
III 1 (11.1) 0 (0.0) 0.273
IV 0 (0.0) 0 (0.0) N/A
V 4 (44.4) 8 (33.3) 0.690
NIH criterion 1 1 (11.1) 1 (4.2) 0.477
NIH criterion 2 7 (77.8) 4 (16.7) 0.002
NIH criterion 3 1 (11.1) 1 (4.2) 0.477
NIH criterion 4 0 (0.0) 12 (50.0) 0.012
Fulfillment of no NIH criteria 1 (11.1) 5 (20.8) >0.999
Fulfillment of one NIH criterion 8 (88.9) 19 (79.2) >0.999
Arterial max SUV, g/mL 2.3 (1.9–3.4) 2.3 (1.8–2.9) 0.486
Mean SUV in blood pool, g/mL 1.5 (1.4–1.8) 1.8 (1.7–2.4) 0.166
TBR 1.5 (1.3–1.8) 1.3 (1.1–1.4) 0.044
Medications at 18F-FDG PET/CT
Glucocorticoid 4 (44.4) 9 (37.5) >0.999
Glucocorticoid dose*, mg/d 0.0 (0.0–7.5) 0.0 (0.0–4.4) 0.648
Methotrexate 2 (22.2) 5 (20.8) >0.999
Azathioprine 1 (11.1) 1 (4.2) 0.477
18F-FDG PET/CT, 18F-fluorodeoxyglucose positron emission tomography/computed tomography; IQR, interquartile range; BMI, body mass index; ESR, erythrocyte 
sedimentation rate; CRP, C-reactive protein; NIH, National Institutes of Health; SUV, standardized uptake value; TBR, target/background ratio.
Data are presented as median (IQR) or n (%).
*Equivalent to prednisolone.
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Fig. 2. Receiver-operating characteristic curves for (A) TBR and (B) combination of TBR and NIH criterion 2 in predicting relapse. TBR, target/background 































Table 3. Factors Associated with Relapse
Univariable analysis Multivariable analysis
HR (95% CI) p value HR (95% CI) p value
Age at 18F-FDG PET/CT, yr 0.957 (0.903–1.014) 0.134
Female (vs. male) sex 1.067 (0.131–8.695) 0.952
Disease duration, yr 1.056 (0.997–1.119) 0.062
Hypertension 1.512 (0.400–5.714) 0.542
Diabetes mellitus 2.262 (0.271–18.858) 0.451
Dyslipidemia 1.038 (0.256–4.212) 0.958
Smoking 1.278 (0.159–10.296) 0.818
BMI, kg/m2 0.897 (0.688–1.170) 0.423
ESR, mm/h 1.112 (1.035–1.195) 0.004*
CRP, mg/L 1.573 (1.005–2.460) 0.047*
Type I (vs. non-type I) 0.265 (0.033–2.137) 0.213
Type IIA (vs. non-type IIA) 0.042 (0.000–24640.130) 0.641
Type IIB (vs. non-type IIB) 1.289 (0.321–5.174) 0.720
Type III (vs. non-type III) 9.155 (0.952–88.046) 0.055
Type IV (vs. non-type IV) N/A N/A
Type V (vs. non-type V) 1.588 (0.424–5.938) 0.492
Presence of NIH criterion 1 (vs. absence of NIH criterion 1) 1.682 (0.206–13.710) 0.627
Presence of NIH criterion 2 (vs. absence of NIH criterion 2) 8.210 (1.688–39.927) 0.009 7.044 (1.424–34.855) 0.017
Presence of NIH criterion 3 (vs. absence of NIH criterion 3) 1.521 (0.187–12.380) 0.695
Presence of NIH criterion 4 (vs. absence of NIH criterion 4) 0.022 (0.000–5.447) 0.174
Fulfillment of one NIH criterion (vs. fulfillment of no NIH criteria) 3.204 (0.393–26.104) 0.277
Use of glucocorticoid 1.413 (0.376–5.316) 0.609
Dose of glucocorticoid 0.993 (0.904–1.091) 0.884
Use of methotrexate 0.797 (0.163–3.896) 0.779
Use of azathioprine 3.116 (0.347–27.951) 0.310
Arterial max SUV, g/mL 1.457 (0.999–2.124) 0.050
Mean SUV in blood pool, g/mL 1.187 (0.545–2.583) 0.666
TBR 14.751 (1.484–146.663) 0.022 11.533 (1.053–126.282) 0.045
HR, hazard ratio; CI, confidence interval; 18F-FDG PET/CT, 18F-fluorodeoxyglucose positron emission tomography/computed tomography; BMI, body mass index; 
ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; NIH, National Institutes of Health; SUV, standardized uptake value; TBR, target/background ratio.
*ESR and CRP were not included in multivariable analysis.
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receiving immunosuppressants, and showed that 18F-FDG up-
take was higher in the former group than in the latter group, sug-
gesting that 18F-FDG PET/CT is a useful tool in detecting active 
disease even during immunosuppressant treatment. Our data 
add to the previous finding that 18F-FDG PET/CT can be useful 
not only for detecting the occurrence of relapse but also for strati-
fying the risk of relapse in patients during clinically inactive dis-
ease. Similar to our present study, a previous prospective cohort 
study consisting of patients with large-vessel vasculitis showed 
that high 18F-FDG PET/CT activity during clinical remission is 
associated with a future clinical relapse.18 However, both TAK 
and giant cell arteritis (GCA) were included in that study, and 
only one patient with TAK was included in the high 18F-FDG 
PET/CT activity group.18 Therefore, it was unclear whether the 
previous finding still applies when confined to patients with 
TAK. Our study suggests that higher 18F-FDG PET/CT activity 
during remission is associated with future relapse, even when 
confined to patients with TAK.
While vascular uptake on 18F-FDG PET/CT during the clini-
cally inactive state of the disease may indicate subclinical vas-
culitis, it may also represent atherosclerosis.19 Due to the lack of 
histologic data in our study, it was difficult to determine wheth-
er the uptake in the vascular wall was due to subclinical vascu-
litis or atherosclerosis. With respect to atherosclerosis in inflam-
matory rheumatic diseases, ESR and CRP, as markers of systemic 
inflammation, are positively associated with atherosclerosis, sug-
gesting that inflammation is a major contributor to accelerated 
atherosclerosis.20,21 On the other hand, acute phase reactants 
poorly reflect the histologically-proven actual vascular wall in-
flammation.22 Therefore, assessment of the correlation between 
TBR and acute phase reactants could aid in speculating the cause 
of vascular uptake. In the present study, there was no significant 
correlation between TBR and ESR (γ=0.055, p=0.762), as well as 
between TBR and CRP (γ=-0.167, p=0.353) (data not shown in 
the results). Given the lack of correlation of TBR with ESR and 
CRP, we presume that the vascular uptake observed in 18F-FDG 
PET/CT favors subclinical vasculitis, rather than atherosclero-
sis, attributed to the inflammation. In any case, it is important 
to perceive patients with vascular uptake on 18F-FDG PET/CT 
during the clinically inactive state of the disease as high-risk pa-
tients for disease relapse.
A previous study has shown that in some patients with GCA, 
which also is a large-vessel vasculitis, vascular uptake on 18F-FDG 
PET/CT does not completely resolve even after treatment.23 Fur-
thermore, a recent study consisting of patients with large vessel 
vasculitis showed that when treatment was reduced, 18F-FDG 
PET/CT activity worsened, despite no change in clinical and se-
rologic disease activity.24 Considering the association between 
vascular uptake on 18F-FDG PET/CT and the risk of relapse, as 
observed in our study, it could be helpful to perform 18F-FDG 
PET/CT in patients with clinically inactive disease and tailor 
treatment accordingly. In our study, although limited by the 
small number, one patient with a relatively high TBR (TBR=1.6, 
which corresponds to the upper quartile among the total pop-
ulation) on 18F-FDG PET/CT received increased medication 
despite clinically inactive disease state and remained relapse 
free, supporting the potential usefulness of adjusting treatment 
based on 18F-FDG PET/CT findings.
The presence of NIH criterion 2 (new or worsening elevation 
of ESR) during the clinically inactive state of the disease was also 
associated with the risk of relapse. The median value of ESR in 
patients fulfilling NIH criterion 2 was 26.0 (23.0–30.0) mm/h 
(data not shown in the results). Considering the normal range 
of ESR (0–15 mm/h for male and 0–20 mm/h for female), ESR 
was only modestly increased in patients who fulfilled NIH cri-
terion 2. Our data suggest that ESR increments during the clin-
ically inactive state of the disease, even in small amounts, might 
indicate an increased risk of future relapse. However, among the 
nine patients who relapsed, two patients did not fulfill NIH cri-
terion 2 at the time of 18F-FDG PET/CT. One of these two pa-
tients had high TBR (TBR=2.1, which corresponds to the top 
3.0% among the total population), suggesting that 18F-FDG PET/
CT results can identify patients at higher risk of relapse who oth-
erwise would have not been identified using NIH criterion 2 
alone. Therefore, TBR can be used as a complementary param-
eter with NIH criterion 2 in predicting the risk of relapse. Nota-
bly, combination of TBR and NIH criterion 2 as a composite pa-
rameter had an excellent predictive accuracy (AUC=0.903).
New or worsening of angiographic feature (i.e. NIH criterion 
4) during apparent clinical remission is common (up to 61%) in 
TAK.2 We also observed that substantial proportion of patients 
(12 of 33, 36.4%) fulfilled NIH criterion 4 during the clinically 
inactive state of TAK. Interestingly, the presence of NIH crite-
rion 4 was more common in patients who did not experience 
relapse compared to those who experienced relapse. Although 
an exact explanation for this observation remains unclear, it 
could be speculated that the presence of NIH criterion 4 indi-
cates an end-stage sequelae, and therefore, is less likely to re-
lapse. Similar observation has been reported in a prospective 
study consisting of 60 patients with TAK, in which a subgroup 
of patients who had new angiographic feature during clinical 
Fig. 3. Comparison of relapse-free survival between patients with high 
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remission had a lower relapse rate (27.3%) than the total study 
population (45%).2 These suggest that the presence of NIH 4 cri-
terion during clinically inactive state might be associated with 
a lower risk of relapse. However, the presence of NIH criterion 
4 did not show a significant association with the risk of relapse 
in Cox regression analysis; therefore, it cannot be concluded that 
the presence of NIH criterion 4 is associated with a lower risk of 
relapse.
We defined clinically inactive disease as a status not meeting 
the NIH criteria for active disease in TAK,2 as used in previous 
studies.7-10 Therefore, patients who fulfilled none of the NIH cri-
teria and those who fulfilled one NIH criterion were both in-
cluded in our study population. An important question arises 
as to whether the risk of relapse is different between patients 
who fulfilled one NIH criterion and those who did not fulfill any 
of the NIH criteria. In the Cox regression analysis, no significant 
increase in the risk of relapse was observed in patients who ful-
filled one NIH criterion compared to those who did not fulfill 
any of the NIH criteria (unadjusted HR: 3.204, 95% CI: 0.393–
26.104, p=0.277). Furthermore, we conducted an additional Cox 
regression analysis including the TBR, number of NIH criterion 
fulfilled (none or one), and an interaction term TBR*number of 
NIH criterion fulfilled (none or one) in the model. The interac-
tion effect was not significant (p=0.761, data not shown in the 
results), indicating that the number of NIH criterion fulfilled, ei-
ther none or one, does not influence the association between 
TBR and risk of relapse.
This study has some limitations. First, due to the retrospec-
tive nature of the study, bias resulting from unmeasured con-
founding cannot be excluded. Second, the number of patients 
was relatively small. Due to the small number of patients and 
events in this study, we were unable to include more than two 
variables in the multivariable analysis. However, compared with 
previous studies,7-10 this study included the largest number of 
patients with TAK who underwent an 18F-FDG PET/CT during 
the clinically inactive state of the disease. Third, the NIH crite-
ria was used to define patients with clinically inactive disease. 
The NIH criteria are suboptimal as a tool for detecting patholog-
ically proven active disease.7 Nevertheless, owing to the lack of 
a gold standard for assessing disease activity in TAK,25 several 
studies have similarly used the NIH criteria for defining active 
disease.7-10
In conclusion, we found that TBR on 18F-FDG PET/CT and the 
presence of NIH criterion 2 during the clinically inactive state 
of the disease could be associated with future relapse. These in-
dicators may help clinicians in identifying patients who are at 
a higher risk of relapse during the clinically inactive state of the 
disease, leading to closer monitoring and earlier adjustment of 
treatment in patients with TAK.
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